Clinical Trial: A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Relapsed or Refractory Lymphomas
Study Type: INTERVENTIONAL
Official Title: A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of IV LP-284 in Adult Patients With Relapsed or Refractory Lympho
Brief Summary:
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors.The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.
Read more